Ionis Pharmaceuticals (NASDAQ: IONS) — Perfil da empresa, notícias e dados financeiros
Ionis Pharmaceuticals develops RNA-targeted drugs to treat severe diseases, aiming to expand its innovative pipeline for better patient outcomes.
Ionis Pharmaceuticals
Ionis Pharmaceuticals is a biotechnology company focused on discovering and developing RNA-targeted therapeutics and nucleic acid-based medicines. The company utilizes antisense technology to discover and deliver treatments for patients with serious diseases, with a primary focus on neurology, cardiometabolic disorders, and rare diseases. Ionis advances its pipeline through both independent commercialization and strategic partnerships with global pharmaceutical leaders. Its proprietary platform allows targeted modulation of gene expression, supporting commercial drugs as well as a clinical pipeline of targeted RNA medicines.
Resumo
Operações
Produtos e/ou serviços de Ionis Pharmaceuticals
- Commercialized Medicines: Key commercial products including SPINRAZA for spinal muscular atrophy and WAINUA for hereditary transthyretin-mediated amyloidosis, generating significant licensing revenues, milestone payments, and commercial royalties through global marketing partnerships.
- Neurology Therapeutics: Clinical development of targeted antisense oligonucleotides addressing severe neurological and neurodegenerative conditions, including advanced trial programs for amyotrophic lateral sclerosis, Alexander disease, Huntington's disease, and rare pediatric neurodevelopmental disorders.
- Cardiometabolic Programs: Development of RNA-targeted medicines designed to address severe metabolic and cardiovascular conditions, including clinical candidates targeting severe hypertriglyceridemia, familial chylomicronemia syndrome, and key cardiovascular risk factors across broad patient populations.
- Rare Disease Therapeutics: Discovery and clinical evaluation of nucleic acid therapeutics focused on rare genetic disorders, utilizing targeted molecular mechanisms to regulate specific gene expression where limited treatment options exist.
- Antisense Drug Technology Platform: Proprietary platform for designing single-stranded RNA and DNA targeted oligonucleotides, enabling precise molecular targeting to inhibit, restore, or modify protein production associated with underlying disease pathways.
- Partnered Licensing Collaborations: Strategic partnerships and licensing agreements with global pharmaceutical companies to co-develop and commercialize candidate molecules, leveraging partner commercial infrastructure for global clinical execution, regulatory submissions, and commercial distribution.
equipe executiva do Ionis Pharmaceuticals
- Brett P. MoniaFounder, CEO & Director
- Elizabeth L. HougenExecutive VP of Finance & CFO
- Patrick R. O'NeilExecutive VP, Chief Legal Officer, General Counsel & Corporate Secretary
- Eric E. SwayzeExecutive Vice President & Head of Research
- Brian BirchlerExecutive Vice President of Corporate & Development Operations
- Richard S. GearyStrategic Consultant
- Eugene SchneiderExecutive VP, Chief Clinical Development & Operations Officer
- Darren GonzalesChief Accounting Officer & Senior VP
- C. Frank BennettExecutive VP & Chief Scientific Officer
- D. Wade WalkeSenior Vice President of Investor Relations
Últimas notícias sobre a Ionis Pharmaceuticals
FDA approves GSK’s Hibsago for chronic hepatitis B
United StatesIonis gains EU recommendation for 880 mg/dL triglyceride indication
United StatesIonis reports Phase 3 kidney drug results
United StatesIonis reports positive Phase 3 ALS trial results
United StatesIonis wins FDA approval for ZANVASTRO
United StatesIonis starts Dravet syndrome drug trial
United States
Histórico de dividendos
Dividendos por ação pagos pela Ionis Pharmaceuticals, por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2000 | — | — | — | $0.1100 |
| FY1999 | — | — | — | $0.6600 |
Principais indicadores financeiros
Resultados divulgados pela Ionis Pharmaceuticals, em USD.
- Cap. de mercado
- 7,3 bi
- Receita (TTM)
- 874,1 mi
- P/L
- —
- LPA (diluído, TTM)
- -3.5
- Dividend yield
- —
- Margem de lucro
- -64.7%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 944 mi | -382 mi | -381 mi | |
| 705,1 mi | -475,1 mi | -453,9 mi | |
| 787,6 mi | -353,7 mi | -366,3 mi | |
| 587,4 mi | -410,2 mi | -269,7 mi |